Work

Development of molecular diagnostic assays of clinical utility for gastric and colorectal cancers management

Year: 2022
Type: dissertation
Abstract: The primary need for molecular diagnostic tests to achieve the utmost of performance indices, the ‎rapid development of new targeted therapy, the emergence of new diagnostic histopathology ‎entities requiring differentiation from similar disease entities, and the increasing cancer patient ‎population have necessitated the continuous development of molecular diagnostic assays to meet ‎the challenges and needs of cancer management.‎ In this thesis I present four (4) molecular diagnostics assays which I developed with the aim of ‎improving certain aspects of their performance indices: Squirrel PCR, mHRMA, MSI-HRMA ‎and the MSI-WES assays. The general hypothesis for this study is that the performance indices ‎of a molecular diagnostics test can be improved by altering certain components of the test or by ‎simply using a different test or detection platform. ‎ The Squirrel PCR assay was developed with the objective of directly sequencing ultrashort DNA ‎segments by Sanger method. The assay resolves the challenges associated with direct sequencing ‎of sub-100bp DNA segments: poor quality sequencing and inaccurate mutation calling. It uses ‎Squirrel primers to elongate - by PCR - the amplicons of ultrashort DNA molecules, thereby ‎enabling good-quality and accurate sequencing by Sanger method. The preliminary data obtained ‎for the Squirrel PCR assay showed that the assay enabled the achievement of 100% genomic and ‎target sequence qualities by Sanger method compared to the design sequences, and 100% ‎accuracy of mutation detection by Sanger method in standard samples. The Squirrel PCR assay ‎allows the circumvention of the use of next-generation sequencing (NGS), pyrosequencing, and ‎sequencing-by-cloning methods, the current laborious, time-consuming, and expensive methods ‎of sequencing short DNA segments. The Squirrel PCR assay therefore would improve the ‎turnaround time and cost-effectiveness of sequencing short DNA molecules and finds ‎application in small sequencing projects in which the available DNA templates are naturally ‎degenerate or degraded. ‎ The consequence of the rapid development of targeted therapy for cancer management is that ‎more genetic targets need to be tested in each patient’s tumour for evidence of predictive ‎variants. For most molecular diagnostics laboratories where limited testing is the routine it is ‎impractical to acquire expensive high throughput mutation detection platforms, and small ‎improvements in performance (in this case, the speed of testing) of existing assays may be all that ‎is required. The mHRMA assay is a high-resolution melting analysis-based assay which combines ‎the exquisite sensitivity of high-resolution melting analysis (HRMA) and the developed capacity ‎to multiplex targets in the HRMA platform, to achieve rapid detection of mutations in colorectal ‎cancer (CRC). The mHRMA assay utilises differential tagging of amplicons with GC-tails – by ‎using GC-tagged primers - to achieve adequate separation of the melting temperatures of ‎amplicons and enable robust duplexing and triplexing of targets. The capacity for multiplexing in ‎the HRMA detection platform makes mHRMA a faster, more cost-effective, and less laborious ‎mutation detection assay than the conventional, single target HRMA. In this development, ‎preliminary data showed that the mHRMA assay can achieve a perfect concordance and 100% ‎sensitivity, specificity, and accuracy compared with the single target HRMA tests.‎ Microsatellite instability (MSI) testing recently achieved additional relevance in cancer ‎management because of its newly discovered predictive value in the use of the highly effective ‎immune checkpoint inhibitors. The implication of its new relevance means that more cancer ‎patients would undergo MSI testing to determine their suitability for immunotherapy. Thus, the ‎need for a faster, less laborious, and probably more cost-effective MSI testing method. The MSI-‎HRMA assay tests MSI in CRC using a combination of established (BAT-25, BAT-26, MONO-‎‎27) and novel (TYMS-26, BCAT-25, MYB, ANGEL2, TP53 (BAT34CA), FBXO46 and TCF4) ‎microsatellite markers in the HRMA detection platform. The selected panels of the MSI-HRMA ‎markers achieved sensitivities, specificities, and accuracies of 91.3-100%, 100% and 100%, ‎respectively, compared to the gold standards. However, because of its detection platform MSI-‎HRMA is easier, faster, and more cost-effective to set up and run than either capillary ‎electrophoresis (CE) or immunohistochemistry (IHC). Also, as shown by the mHRMA assay, the ‎MSI-HRMA can be multiplexed to further reduce the labour, cost and turnaround time ‎associated with MSI testing. ‎ One advantage of using NGS for mutation detection is that huge numbers of variants, including ‎clinically relevant single nucleotide variants (SNVs) as well as microsatellite-based indels, can be ‎tested in single NGS experiments, thereby obviating the necessity for separate experiments for ‎SNV detection and for MSI testing. The MSI-WES was designed as a simple strategy for ‎testing MSI in gastric cancer (GCa) using level 2 whole exome sequencing (WES) data as ‎recorded in variant call format (vcf) files. MSI-WES simply counts the insertions and deletions ‎‎(indels) occurring within microsatellite contexts and uses the count-based indices as MSI scores. ‎Based on a well-defined threshold of MSI scores MSI-WES robustly classified each GCa case ‎into MSI or MSS. MSI-WES achieved a near-perfect concordance with the PCR-based MSI test, ‎and sensitivity, specificity, and accuracy of 100%, 99.03% and 99.22%, respectively. The ‎attraction for MSI-WES is its simplicity of MSI-testing strategy devoid of complex statistical ‎permutations. Furthermore, MSI testing is performed on the same processed vcf files from which ‎other clinically relevant mutation types are extracted. ‎ Each of the four assays were validated to variable extents as discussed in the thesis. ‎
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7218273505
Cites: 357
Cited by:
Related to: 10